Retatrutide in Australia
Retatrutide is an investigational triple agonist of GLP-1, GIP and glucagon receptors. It is not ARTG-registered in Australia in 2026. The only lawful Australian pathway is via TGA SAS-B with an AHPRA-registered doctor — and in most cases the clinically appropriate first-line option is Mounjaro or Wegovy.
AHPRA-registered doctors
Australian doctors only prescribe retatrutide via TGA SAS-B when there is a documented clinical reason not to use an ARTG-registered alternative.
Not ARTG — SAS-B only
Retatrutide is in phase 3 trials. It is not approved by the TGA as a finished product. Any "Australian retatrutide" sold without a prescription is illegal.
TGA-licensed compounding
Where SAS-B is granted, dispensing must be through a TGA-licensed Australian compounding pharmacy operating under PIC/S GMP — never offshore vendors.
What is retatrutide?
Retatrutide (development code LY3437943) is an investigational once-weekly subcutaneous injection developed by Eli Lilly. It activates three gut and metabolic hormone receptors at once — GLP-1, GIP, and glucagon. The first two are the same pair tirzepatide hits; adding glucagon-receptor activity is thought to increase basal energy expenditure on top of appetite suppression and insulin sensitisation.
Phase 2 trial data published in The New England Journal of Medicine in 2023 showed mean weight loss of around 24% of body weight at 48 weeks at the highest 12 mg dose — higher than any GLP-1 monotherapy or GIP/GLP-1 dual agonist has reported. The phase 3 TRIUMPH program is ongoing and expected to support a US FDA submission across 2025–2026.
Australian regulatory reality (2026)
Retatrutide is not listed on the Australian Register of Therapeutic Goods. It cannot be dispensed at a regular Australian pharmacy. The only lawful Australian access pathway is via the TGA Special Access Scheme Category B — a per-patient, per-case notification lodged by an AHPRA-registered medical practitioner — and dispensing must be through a TGA-licensed compounding pharmacy. In practice, most AHPRA-registered prescribers will recommend the ARTG-registered alternatives (Mounjaro or Wegovy) first, because both have established long-term safety data and approved supply.
Cautions
Same cautions as other incretin drugs (pancreatitis, gallbladder disease, MTC/MEN-2 history, pregnancy/breastfeeding), plus theoretical effects on glucose handling and heart rate from glucagon-receptor activation. Long-term human safety data is not yet available. This is the primary reason it is not a first-line Australian option in 2026.
Retatrutide vs tirzepatide vs semaglutide
For most Australian patients, the clinically appropriate option in 2026 is tirzepatide or semaglutide — both are ARTG-registered, both have long-term outcomes data, and both are dispensed from any Australian pharmacy.
| Retatrutide | Tirzepatide (Mounjaro) | Semaglutide (Wegovy / Ozempic) | |
|---|---|---|---|
| Mechanism | GLP-1 + GIP + glucagon (triple agonist) | GLP-1 + GIP (dual) | GLP-1 (single) |
| Australian regulatory status (2026) | Not ARTG-registered — SAS-B only | ARTG-registered (Mounjaro) | ARTG-registered (Wegovy / Ozempic) |
| Phase of evidence | Phase 3 (ongoing) | Approved, long-term outcomes data | Approved, multi-year outcomes data |
| Average weight loss (trial data) | ~24% at 48 wks (phase 2) | ~20–22% at 72 wks | ~14–17% at 68 wks |
| Where dispensed in AU | TGA-licensed compounding pharmacy (per-case) | Any Australian pharmacy | Any Australian pharmacy |
| Typical AUD cost / month (2026) | $400–$700 (compounded, per case) | $400–$650 | $300–$520 |
Read the full breakdown: Tirzepatide Australia · Semaglutide Australia
How an Australian doctor would actually handle a retatrutide enquiry
- 1. Free 5-minute pre-qualification
Screening on BMI, comorbidities, medications and prior weight-management treatment.
- 2. $99 telehealth consult
AHPRA-registered Australian doctor reviews your case. Most patients are clinically appropriate for ARTG-registered tirzepatide or semaglutide first.
- 3. If retatrutide is clinically justified
The doctor lodges a TGA SAS-B notification. This is a per-case decision — not a default product. Many AHPRA doctors will decline to prescribe retatrutide while ARTG alternatives exist.
- 4. TGA-licensed compounding pharmacy dispense
If approved, dispensing is via a TGA-licensed Australian compounding pharmacy with cold-chain shipping. Never offshore vendors, never Customs-imported product.
"Retatrutide Australia" sold online is illegal
Sites that sell retatrutide as a "research peptide" — including retatrutide.com.au, australianpeptidestore, purepeptix and similar — are not AHPRA-licensed prescribers and not TGA-licensed compounding pharmacies. The product they ship has no guarantee of identity, potency, sterility or endotoxin compliance. Buying, possessing or importing retatrutide outside the AHPRA → SAS-B → TGA-licensed-pharmacy pathway is an offence under state Poisons Acts and the Customs Act. See why staying local matters.
Retatrutide Australia — FAQs
- Is retatrutide legal in Australia?
- Retatrutide is not yet ARTG-registered in Australia — it is still in late-phase clinical trials (TRIUMPH program) and has not received TGA marketing approval. That means it cannot be lawfully bought from an Australian pharmacy as a finished product, and importing it yourself from offshore 'research peptide' sites is an offence under the Customs Act. The only lawful Australian pathway in 2026 is via the TGA Special Access Scheme Category B (SAS-B), prescribed by an AHPRA-registered doctor on a strict per-case basis, dispensed by a TGA-licensed compounding pharmacy. Most prescribers will recommend the ARTG-registered alternative (Mounjaro / tirzepatide or Wegovy / semaglutide) first.
- What is retatrutide and how is it different from tirzepatide?
- Retatrutide is an experimental triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously. Tirzepatide (Mounjaro) activates only GLP-1 and GIP. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite-suppression and insulin-sensitising effects shared with GLP-1/GIP drugs. Phase 2 trial data published in 2023 (TRIUMPH-1) showed average weight loss of around 24% at 48 weeks at the highest dose — higher than reported for tirzepatide or semaglutide. Phase 3 trials are ongoing.
- Can an Australian doctor prescribe retatrutide?
- Only via a TGA SAS-B notification, and only when the prescriber can clinically justify it for a specific patient. Most Australian AHPRA-registered prescribers will exhaust the ARTG-registered options first — Mounjaro (tirzepatide), Wegovy (semaglutide) — because they have ARTG approval, established long-term safety data, and routine PIC/S-compliant supply. Retatrutide is generally not prescribed as a first-line option in Australia in 2026.
- What about retatrutide sold on Australian websites?
- Sites like retatrutide.com.au, australianpeptidestore, and purepeptix are selling retatrutide as a 'research peptide' — they are not licensed Australian pharmacies, the product is not prescribed, and it carries no guarantee of identity, potency, sterility, or endotoxin compliance. Buying or possessing retatrutide outside the lawful AHPRA-prescriber + TGA-licensed-compounding-pharmacy pathway is an offence under state Poisons Acts. There have been documented seizures by Australian Border Force.
- How much does retatrutide cost in Australia?
- There is no published Australian retail price because retatrutide is not ARTG-registered. Where it is compounded under SAS-B in 2026 — which is rare and clinician-led — the per-month cost typically sits in the AUD $400–$700 range depending on dose and the compounding pharmacy. Mounjaro (tirzepatide) and Wegovy (semaglutide) are usually the lower-cost, evidence-backed alternatives for most weight-management cases.
- What are the side effects of retatrutide?
- Trial data shows the same gastrointestinal pattern as other incretin drugs: nausea, vomiting, diarrhoea, and constipation during dose titration. The triple-agonist mechanism may add increased heart rate and theoretical effects on glucose handling from glucagon-receptor activation — these are being characterised in phase 3 trials. Long-term safety data is not yet available. This is one of the main reasons AHPRA-registered Australian doctors generally recommend tirzepatide or semaglutide first.
- Am I eligible for retatrutide via an Australian doctor?
- Practically, the answer is usually no in 2026 unless you have already trialled ARTG-registered GLP-1 or GIP/GLP-1 therapies (tirzepatide, semaglutide) and have a documented clinical reason why a triple-agonist is appropriate. Final eligibility is a clinical decision at consultation. Most patients are better served starting with Mounjaro or Wegovy — both have published long-term outcomes data and are routinely dispensed from Australian pharmacies.
- When will retatrutide be available in Australia?
- Eli Lilly's phase 3 TRIUMPH program is expected to read out across 2025–2026, with TGA / ARTG registration potentially following 12–18 months after a successful FDA submission. Realistically that places routine Australian availability around 2027–2028. Until then any 'Australian retatrutide' product outside the SAS-B pathway is not a legitimate Australian medicine.
Related Australian peptide pages
Start with the legality hub if you're new to TGA SAS-B prescribing, or browse the other Australian peptide landings.
Medically reviewed by the PeptideDoctorAU Medical Review Panel — last reviewed 29 May 2026. See the panel.
Talk to an AHPRA-registered Australian doctor — $99
Take the free 5-minute pre-qualification. If you're suitable, you'll be matched with an AHPRA-registered doctor who will explain whether tirzepatide, semaglutide, or — in rare clinically-justified cases — a SAS-B retatrutide pathway is appropriate for you.
Start free assessment